Myeloma Minute: Making Myeloma Matter
|
| EDUCATION | Diversity
Making Myeloma MatterDid you know that black men and women are diagnosed with myeloma at approximately twice the rate as the combined average for all ethnic backgrounds? Unfortunately, we don’t yet know the reasons for these rates. The African American community needs access to resources to better recognize symptoms, understand their diagnosis, and research treatment options for this disease. That’s why the International Myeloma Foundation has launched a mailing list at myeloma.org/diversity-multiple-myeloma. Sign up so that you can be the first to know of any new developments, studies, or programs that may affect you and your loved ones in the African American community.
|
|
|
| INSPIRATION | Myeloma Voices
|
| EDUCATION | Event
|
From Overwhelmed Myeloma Patient to Support Group Leader |
Register NOW for a Regional Community Workshop in Birmingham, Alabama |
|
Diagnosed with multiple myeloma in 2012, Frank Morelli shares how he and his wife Debbie went from being overwhelmed with their own situation to helping others at their support group. Listen to hear sentiments such as this one: “I understand that [at the] next doctor appointment, things could be traumatically different. I think that’s what’s important about understanding myeloma. Also, it’s part of your education, and the benefit of being part of the support group and the information that we get from people like the IMF. You’re prepared.” |
The IMF will conduct a Regional Community Workshop in Birmingham, AL, on Saturday, October 6, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Luciano J. Costa, MD, PhD (Associate Professor of Medicine, University of Alabama at Birmingham), Kelly Godby, MD (Assistant Professor of Medicine, UAB Hematology/Oncology, University of Alabama at Birmingham), and Charise Gleason, MSN, NP-BC, AOCNP (Winship Cancer Institute, Emory University, Atlanta). |
|
|
|
|
| INNOVATION | Drug Development
Daratumumab Approved in Europe for First-line Treatment of Patients with Multiple MyelomaThe European Commission has granted approval of Darzalex® (daratumumab), a CD38-directed antibody, for first-line treatment of patients with multiple myeloma. The approval authorizes the use of Darzalex in combination with Velcade® (bortezomib), melphalan, and prednisone (VMP), for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). This approval is based on results of the phase III ALCYONE (MMY3007) study.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
September 8, 2018 September 15, 2018 September 22, 2018 September 22, 2018 September 22, 2018 September 22, 2018 September 23, 2018 |
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year